Efficacy of Viral RNA Processing Inhibitors in Controlling HIV-1 Replication in vivo

病毒 RNA 加工抑制剂在体内控制 HIV-1 复制的功效

• 批准号: 379093
• 负责人: Wong Raymond
• 金额: $ 9.83万
• 依托单位: Sunnybrook Research Institute (Toronto, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-11-01 至 2020-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=379093&lang=en
• 关键词: Antiviral; Chemical Biology; Drugs; Flow Cytometry; High Throughput Screens; Hiv/Aids; In Vivo Validation; Mice; Rna; Stem Cells

Antiretroviral therapies (ARTs) for HIV-1 infection target the viral lifecycle and delay the progression of those infected to AIDS. However, the effectiveness of these ARTs are plagued by a rise in drug-resistant HIV strains present in over 7-24% of newly

针对HIV-1感染的抗逆转录病毒疗法（ART）针对病毒的生命周期，并延迟感染者向AIDS的进展。然而，这些抗逆转录病毒疗法的有效性受到了耐药HIV菌株增加的困扰，这些耐药HIV菌株存在于超过7-24%的新感染者中。